drugset / Trial / NCT00285298
Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients
Phase 3
Completed
39 enrolled
Walter Reed Army Medical Center
National Kidney Foundation, United States · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the investigators study is to assess the impact of therapy with Pentoxifylline (PTF), a nonspecific phosphodiesterase inhibitor, on kidney function in patients at high-risk for progression to end-stage renal disease. The investigators hypothesize that therapy with Pentoxifylline will slow progression of kidney disease over time.
Timeline
- Start
- 2006-01
- Primary completion
- 2008-04
- Completion
- 2008-04
Publications
- Results Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009 Apr;53(4):606-16. doi: 10.1053/j.ajkd.2008.11.026. Epub 2009 Feb 12.
- Colombijn JM, Hooft L, Jun M, Webster AC, Bots ML, Verhaar MC, Vernooij RW. Antioxidants for adults with chronic kidney disease. Cochrane Database Syst Rev. 2023 Nov 2;11(11):CD008176. doi: 10.1002/14651858.CD008176.pub3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentoxifylline | Small molecule | 400 mg | — |